LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Digital Platform Technology Aims to Disrupt 50-Year-Old PCR Testing for Similar-Symptom Pathogens

By LabMedica International staff writers
Posted on 14 Dec 2022
Print article
Image: A breakthrough technology intends to reshape the future of diagnostic testing (Photo courtesy of IdentifySensors)
Image: A breakthrough technology intends to reshape the future of diagnostic testing (Photo courtesy of IdentifySensors)

Disease caused by bacteria, pathogens and pollutants presents a significant threat to human health, safety and security. Now, a disruptive new diagnostic testing platform intends to be completely different from any others currently on the market and reshape the future of diagnostic testing.

IdentifySensors Biologics (Shaker Heights, OH, USA), along with leading researchers at Purdue University (West Lafayette, IN, USA), has developed an innovative nanosensor technology, Check4. The technology platform uses electronic nanosensors to detect the genetic material of numerous pathogens, including the coronavirus that causes COVID-19. Check4 is intended to be as accurate as a PCR test in minutes without a prescription. A nanosensor cartridge interacts with saliva to produce a distinguishable electronic signal for positive or negative results with accuracy that rivals PCR tests. Using saliva and the user’s smartphone, results will be delivered within minutes.

The Check4 testing platform consists of two parts: a reusable Bluetooth reader about the size of a cell phone; and a disposable test cartridge that attaches to the reader. As many as three pathogens can be detected simultaneously from a single test sample. Digital graphene sensors inside the cartridges target conserved regions of the genome allowing for high sensitivity and specificity. The sensors inside the disposable cartridges can be functionalized to detect a wide range of similar-symptom pathogens. Multiplex tests are being developed for respiratory (COVID, RSV and influenza), stomach (Norovirus, Rotavirus and Adenovirus) and sexually transmitted pathogens (HIV, Hepatitis, Chlamydia, Gonorrhea and Herpes). Other tests in development include SEPSIS, MRSA, Lyme and equatorial pathogens such as Zika, Dengue, Yellow Fever and West Nile.

Check4 is easy to use and fast, accurate, and affordable. It is intended to avoid the limitations of current molecular tests such as enzymatic reactions, amplification, sample preservation or sample transportation, which can introduce artifacts and raise the risk of false positives. The technology avoids costly elements used by laboratory-based molecular tests such as enzymes and reagents that are in short supply. It also eliminates the need for laboratory technicians, diagnostic machines and personal protective equipment. The reusable reader is intended to cost about USD 130.

Related Links:
IdentifySensors Biologics
Purdue University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more